Cancer Research Cell Death Mechanisms and Cancer Therapy EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Browd, S. R.
Right arrow Articles by Fults, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Browd, S. R.
Right arrow Articles by Fults, D. W.
[Cancer Research 66, 2666-2672, March 1, 2006]
© 2006 American Association for Cancer Research

Cell, Tumor, and Stem Cell Biology

N-myc Can Substitute for Insulin-Like Growth Factor Signaling in a Mouse Model of Sonic Hedgehog–Induced Medulloblastoma

Samuel R. Browd1, Anna M. Kenney2, Oren N. Gottfried1, Joon Won Yoon3, David Walterhouse3, Carolyn A. Pedone1 and Daniel W. Fults1

1 Department of Neurosurgery, University of Utah School of Medicine, Salt Lake City, Utah; 2 Department of Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York; and 3 Department of Pediatrics; Northwestern University Feinberg Medical School and the Children's Memorial Hospital Research Center; Chicago, Illinois

Requests for reprints: Daniel W. Fults, Department of Neurosurgery, University of Utah School of Medicine, 30 North 1900 East, Salt Lake City, UT 84132-2303. Phone: 801-581-6908; Fax: 801-581-4385; E-mail: daniel.fults{at}hsc.utah.edu.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Medulloblastoma is a malignant brain tumor that arises in the cerebellum in children, presumably from granule neuron precursors (GNP). Advances in patient treatment have been hindered by a paucity of animal models that accurately reflect the molecular pathogenesis of human tumors. Aberrant activation of the Sonic hedgehog (Shh) and insulin-like growth factor (IGF) pathways is associated with human medulloblastomas. Both pathways are essential regulators of GNP proliferation during cerebellar development. In cultured GNPs, IGF signaling stabilizes the oncogenic transcription factor N-myc by inhibiting glycogen synthase kinase 3ß–dependent phosphorylation and consequent degradation of N-myc. However, determinants of Shh and IGF tumorigenicity in vivo remain unknown. Here we report a high frequency of medulloblastoma formation in mice following postnatal overexpression of Shh in cooperation with N-myc. Overexpression of N-myc, alone or in combination with IGF signaling mediators or with the Shh target Gli1, did not cause tumors. Thus, Shh has transforming functions in addition to induction of N-myc and Gli1. This tumor model will be useful for testing novel medulloblastoma therapies and providing insight into mechanisms of hedgehog-mediated transformation. (Cancer Res 2006; 66(5): 2666-72)


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Medulloblastoma is a malignant brain tumor that arises in the cerebellum in children. Several lines of evidence implicate granule neuron precursors (GNP) in the external granule layer (EGL) of the developing cerebellum as likely cells of origin for certain classes of medulloblastomas (reviewed in ref. 1). For example, cells that compose a preneoplastic stage of medulloblastoma colocalize with GNPs in the EGL and they express molecular markers of immature granule neurons (2). Recently, another possible medulloblastoma cell of origin has been identified: a neural progenitor located in the cerebellar white matter and expressing both nestin and prominin (3). Signal transduction pathways that stimulate proliferation and inhibit differentiation of GNPs and other neural progenitor cells during development have been implicated in medulloblastoma. Thus, understanding the mitogenic functions of these pathways will yield insights into medulloblastoma formation.

In mice and humans, GNPs undergo a rapid, postnatal expansion phase in the EGL (reviewed in ref. 4). This presents a vulnerable setting for transforming events leading to tumorigenesis. GNP proliferation requires Sonic hedgehog (Shh) signaling (reviewed in ref. 5). GNP expansion and survival are also promoted by insulin-like growth factor (IGF) signaling (reviewed in ref. 6). Mutations that activate the Shh pathway occur in human medulloblastoma (7, 8). Increased IGF pathway activity has also been observed in medulloblastoma, suggesting that the pro-proliferative effects of this pathway may play an accessory or permissive role in medulloblastoma formation or maintenance (9).

Efforts to model medulloblastoma formation in mice have suggested conservation of the developmental and tumorigenic roles of the Shh and IGF pathways. For example, genetic manipulations that activate Shh signaling in the developing mouse cerebellum induce tumors that closely resemble human medulloblastoma. Targeted disruption of the Patched gene, which encodes the inhibitory component of the Shh response machinery, predisposes Patched+/– mice to medulloblastoma formation (10). Retroviral transfer and expression of Shh itself in the cerebellum induce EGL hyperplasia and medulloblastoma (11, 12). Consistent with these results, enhancing activity of Smoothened, the positively responding component of the Shh receptor apparatus, also promotes medulloblastoma development in transgenic mice (13). Enhanced IGF pathway activity causes cerebellar hyperplasia in mice (14) and contributes to Shh-mediated medulloblastoma formation (15).

A disadvantage to relying on transgenesis-mediated, ectopic gene expression or ablation for modeling human tumors is the difficulty in controlling temporal regulation of gene expression in a cell type–specific manner. This is particularly important with regard to medulloblastoma because the presumed cells of origin proliferate after birth. To target GNPs during their expansion phase, we have used the RCAS/tv-a system, which allows postnatal gene transfer in a cell type–specific manner (16). This system uses replication-competent avian leukosis virus (ALV) splice-acceptor (RCAS) vectors, derived from the avian retrovirus ALV (subgroup A), and a transgenic mouse line (Ntv-a) that produces TV-A (the receptor for ALV-A) under the control of the Nestin gene promoter. Nestin is an intermediate filament protein expressed by neuronal and glial progenitors (17). After TV-A-mediated viral infection, the RCAS provirus integrates into the host cell genome where the transgene is expressed from a spliced message under the control of the constitutive retroviral promoter, long terminal repeat. Combinations of genes can be transferred to individual cells by infecting them with multiple RCAS vectors carrying different genes. This makes it possible to determine whether different oncogenes cooperate to induce tumor formation in vivo.

Using the RCAS/tv-a system to target gene expression to nestin-expressing neural progenitors in newborn mice, we previously reported that activation of phosphoinositide 3-kinase (PI3K) signaling by IGF-II synergizes with Shh to enhance medulloblastoma formation (15). Working with cultured GNPs, Kenney et al. (18) described a two-pronged mechanism whereby Shh and PI3K signaling pathways cooperate to promote proliferation by converging on the oncogenic transcription factor N-myc. N-myc is a critical regulator of Shh-induced GNP proliferation (18–21) and its expression is up-regulated in human medulloblastomas (13, 22). Shh signaling directly stimulates N-myc gene transcription (19, 20). IGF-mediated PI3K signaling stabilizes the N-myc protein by inhibiting glycogen synthase kinase 3ß (GSK3ß)–dependent phosphorylation and consequent degradation of N-myc (18). Consistent with this model, we detected abundant, endogenous N-myc in medulloblastomas induced in mice by retroviral transfer of Shh and IGF-II (15).

To test the hypothesis that Shh induction of N-myc plays an important role in medulloblastoma tumorigenesis and that an important function of the IGF pathway in vivo is to stabilize N-myc, we used the RCAS/tv-a system to transfer N-myc to nestin-expressing cerebellar progenitors in mice. Targeting nestin+ cells enabled us to make direct comparisons with our previous results. We found an enhancing effect of N-myc on Shh-induced medulloblastoma formation. A mutant N-myc allele encoding a T50A amino acid substitution had a more potent enhancing effect than wild-type N-myc. This amino acid substitution stabilizes the N-myc protein by preventing GSK3ß-catalyzed phosphorylation of N-myc (18). These results are consistent with a model in which IGF/PI3K signaling promotes medulloblastoma formation by stabilizing N-myc. Transfer of N-myc, alone or in combination with IGF signaling mediators or with the Shh target Gli1, did not induce tumors, suggesting that Shh has unique and essential transforming functions in GNPs distinct from induction of N-myc and Gli1.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Transgenic mice. Production of the Ntv-a transgenic mouse line has been previously described (23). The mice used in these experiments are mixtures of the following strains: C57BL/6, BALB/C, FVB/N, and CD1.

Vector constructs. The RCAS-N-myc vector was constructed by ligating a PCR-generated cDNA sequence corresponding to exons 2 and 3 of the wild-type N-myc gene into parent retroviral vector, RCASBP(A) (16). RCAS-N-mycT50A was derived by site-directed mutagenesis as previously described (18). RCAS-N-mycT50A has a single Flag epitope (DYKDDDDKP) on the NH2 terminus of the encoded protein. To detect expression of the virally transferred protein in formalin-fixed, paraffin-embedded tissue sections, we prepared an additional epitope-tagged version of RCAS-N-mycT50A by appending six repeats of the sequence encoding the human c-Myc epitope (MEQKLISEEDLN) recognized by monoclonal antibody 9E10. The Flag epitope sequence was not present in the Myc-tagged vector construct. Construction and characterization of RCAS-Shh, which has six repeats of the influenza virus hemagglutinin (HA) epitope (YPYDVPDYA), have previously been described (12). RCAS-IGF-II and RCAS-Akt have previously been described (15). RCAS-GLI(-AT) encodes a transcriptionally active, NH2-terminal deleted version of Gli1 (24).

In vivo infection of transgenic mice. RCAS virus production in DF-1 cells and transfer of genes to nestin-expressing, neural progenitors were carried out as previously described (12). We injected mice within 72 hours after birth because the pool of nestin+ cells producing ALV-A receptors diminishes progressively afterward. We injected virus-producing cells rather than cell-free virus stocks to achieve persistently high virus titers at the injection sites. The mice were sacrificed 12 weeks after injection or sooner if they showed signs of increased intracranial pressure. The brains were fixed in formalin, embedded in paraffin, and sectioned for immunohistochemical analysis as previously described (12).

Immunocytochemistry. To analyze protein expression in tissue sections, we used a previously described immunoperoxidase staining method (12). We used the following monoclonal antibodies (and dilutions) from the indicated commercial sources: 9E10 (1:50), human c-Myc (Santa Cruz Biotechnology, Santa Cruz, CA); F7 (1:50), HA (Santa Cruz Biotechnology); 2F11 (1:100), 70-kDa neurofilament protein (Dako, Carpinteria, CA); TuJ1 (1:400), ßIII tubulin (Research Diagnostics, Flanders, NJ); Mab377 (1:100), NeuN (Chemicon, Temecula, CA); T4026, ß-tubulin (Sigma, St. Louis, MO), CD31 (1:50), platelet/endothelial cell adhesion molecule 1 (PECAM-1; Santa Cruz Biotechnology). We used polyclonal antibodies to detect expression of GFAP (1:1,000; Dako), TrkC (1:25; R&D Systems, Minneapolis, MN), N-myc (1:100; C-19; Santa Cruz Biotechnology), cyclin D2 (1:200; M-20; Santa Cruz Biotechnology), Ki67 (1:1,000; Vector Laboratories, Burlingame, CA), and von Willebrand factor (1:200; Dako).

Immunoblotting. Brain tissue samples (100-400 mg) were homogenized in 1 mL lysis buffer [50 mmol/L Tris (pH 7.4), 150 mmol/L NaCl, 1 mmol/L EDTA, 1% Triton X-100, Sigma protease inhibitor cocktail, 100 µmol/L phenylmethylsulfonyl fluoride]. For each sample, 50 µg of total protein were separated on 8% SDS-polyacrylamide gels and then transferred to nitrocellulose membranes. Membranes were immersed in a blocking solution (5% milk, 0.1% Triton X-100, 25 mmol/L Tris, 138 mmol/L NaCl, 2 mmol/L KCl) and incubated with primary antibody (rabbit anti-N-myc C-19; Santa Cruz Biotechnology). Immunoreactivity was detected using horseradish peroxidase–conjugated secondary antibody and enhanced chemiluminescence.

Gli1 transactivation assays. We prepared GLI(-AT) by removing a HindIII/XhoI fragment from the 5'-end of the Gli1 cDNA, and the negative control GLI(-TAD) by deleting from the 3'-end the AccI fragment containing the transactivation domain (24). We used 0 to 0.5 µg of each effector construct, 0.01 µg of the Renilla luciferase reporter vector (transfection efficiency control), and 0.25 µg of the 8XGLI-lc-luc luciferase reporter (contains 8 consensus GLI binding elements) for the cotransfection experiments. In each case, DNA was mixed with 3 µL of Lipofectamine 2000 reagent in 0.2 mL OptiMEM (Invitrogen, Carlsbad, CA), incubated for 20 minutes at room temperature, and then applied to 105 HeLa cells in 1 mL OptiMEM. Cells were incubated for 5 hours in a CO2 incubator before addition of growth medium. After 24 hours, lysates were prepared for luciferase and Renilla luciferase assays. Luciferase activity was normalized to the Renilla luciferase activity of the same sample (Promega, Madison, WI).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
N-myc synergizes with Shh in medulloblastoma formation. To investigate the role of N-myc in Shh-induced medulloblastoma formation, we expressed N-myc ectopically (alone and in combination with Shh) in the postnatal mouse cerebellum. To achieve, this, we generated an RCAS vector carrying the N-myc gene and then prepared retrovirus packaging cells producing RCAS-N-myc and RCAS-Shh. A pellet containing 105 cells was injected into the lateral cerebellum of newborn mice expressing the tv-a transgene under control of the Nestin promoter. For experiments in which infection with both RCAS-Shh and RCAS-N-myc was the goal, the cell pellet was prepared by mixing equal numbers of both retrovirus-producing cells. The Nestin promoter directs expression of TV-A to central nervous system progenitor cells, thereby ensuring that RCAS retroviruses infect immature precursor cells in the injected region of the cerebellum. At the developmental stage when the injections took place, the majority of cells expressing TV-A in the cerebellum are predicted to be GNPs (4). The recently discovered prominin+/nestin+ progenitors, located in the cerebellar white matter, do not proliferate in response to Shh and may therefore represent cells of origin for medulloblastomas that are not associated with Shh pathway activity (3). Targeting ectopic Shh to these cells is unlikely to be tumorigenic.

Animals showing increased head circumference (a sign of internal hydrocephalus) or debilitation were sacrificed and immediately analyzed. All remaining mice were sacrificed for analysis 12 weeks after injection. To assess tumor formation, the brains were dissected, sectioned, and subjected to H&E staining as well as immunostaining for markers characteristic of immature neurons, mature neurons, and medulloblastoma. Consistent with our previous results (15), medulloblastomas were detected in 15% of mice injected with cells producing RCAS-Shh alone (Table 1). Interestingly, this is similar to the percentage of Patched+/– mice reported to develop medulloblastoma (10, 25). These results suggest that the effect of RCAS-mediated ectopic expression of Shh in GNPs is comparable to endogenous, constitutive pathway activation and that both methods of activating the Shh pathway render GNPs similarly susceptible to secondary transforming events.


View this table:
[in this window]
[in a new window]
  		Table 1. Medulloblastoma induction by RCAS-mediated transfer in Ntv-a mice

 
As shown in Table 1, tumor incidence was increased in mice infected with RCAS-Shh and RCAS-N-myc together (47%; P = 0.0014). The incidence of tumor formation was comparable to that we previously reported after transfer of Shh in combination with upstream and downstream components of the PI3K pathway [i.e., IGF-II (39%) and activated Akt (48%); ref. 15]. No tumors were found, however, in mice injected with RCAS-N-myc alone (Table 1). Thus, N-myc can substitute for PI3K pathway activation in enhancing Shh-dependent medulloblastoma formation but N-myc alone is not sufficient for GNP transformation.

Tumors induced by Shh + N-myc arise from neuronal precursors and resemble human medulloblastomas. The tumors induced by Shh + N-myc arose in the dorsolateral cerebellum at the injection sites (Fig. 1A and B). Microscopically, these tumors closely resembled human medulloblastomas and they appeared to be identical to tumors induced by Shh alone. They were composed of homogeneous, densely packed sheets of cells with hyperchromatic nuclei and scant cytoplasm (Fig. 1C) with frequent mitotic figures (Fig. 1C, arrows). We observed foci of EGL hyperplasia adjacent to some of the tumors as we previously reported in mice injected with RCAS-Shh alone (12). This supports the concept that mitogenic stimulation of GNPs by Shh is a precursor stage of medulloblastoma (27).


Figure 1
View larger version (97K):
[in this window]
[in a new window]
  		Figure 1. Histopathology of medulloblastomas induced by Shh + N-myc. A, midsagittal brain section showing tumor in the dorsolateral cerebellum (Cb) causing obstructive hydrocephalus with dilation of the lateral ventricle (V) in the forebrain. B, medulloblastoma, induced by Shh + N-mycT50A, invading the adjacent cerebellar cortex (Cb; H&E). C, cytoarchitecture pattern of medulloblastoma induced by Shh + N-mycT50A. Arrows, mitotic figures (H&E). D to H, immunoperoxidase staining of medulloblastomas induced by Shh + N-myc, showing cytoplasmic expression of ßIII tubulin (D), TrkC (F), and synaptophysin (G), and nuclear expression of NeuN (E) in tumor cells. D, tumor cells infiltrating the molecular layer (Mo) of the cerebellar cortex. Immunoreactivity for ßIII tubulin is visible in neurons in the Purkinje layer (Pu) and the internal granule layer (IGL). H, von Willebrand factor in blood vessels (arrows) but in tumor cells. Bar: 390 µm (B), 38 µm (C and G), 77 µm (D), and 19 µm (E and F).

 
To assess the differentiation status of tumors induced by Shh + N-myc, we carried out an immunocytochemical analysis using antibodies for neural differentiation antigens. All tumors showed abundant ßIII tubulin in the cytoplasm and NeuN in the nucleus (Fig. 1D-E), markers of early neuronal differentiation (26, 27). We also observed cytoplasmic TrkC, a high-affinity neurotrophin receptor, which is expressed in human medulloblastomas (Fig. 1F; ref. 28). All tumors showed focal expression of synaptophysin, a neurosecretory protein expressed in 94% of human medulloblastomas (ref. 29; Fig. 1G). We did not detect expression of neurofilament protein, a marker of terminally differentiated neurons, in any tumor. As previously reported (12), immunoreactivity for the astrocytic marker GFAP was visible only in processes of entrapped astrocytes and was not seen in tumor cells. The preferential expression of neuronal markers supports an origin of the induced tumors from neuronal precursors.

It is possible that ectopic expression of Shh may drive nestin+ cerebellar progenitors away from a glial fate, concurrent with enhancing proliferation and promoting transformation. Several studies from the developmental biology literature, however, suggest that this is unlikely. In the developing spinal cord, Shh drives expression of early oligodendrocyte markers (30). In the cerebellum, Shh promotes postnatal differentiation of an already committed astrocytic lineage, Bergman glia (31). Moreover, exposure of GNPs, isolated from the postnatal EGL, to Shh and bone morphogenetic proteins promotes astroglial differentiation (32).

Nestin is not restricted to neural progenitor cells and is also found in embryonic capillaries in brain and other organs (33). We cannot exclude the possibility that our RCAS vectors infected immature endothelial cells. Nevertheless, expression of neural antigens in the induced tumors indicates that the most likely target cells are undifferentiated neural progenitors, not vascular stem cells. Furthermore, when we probed tumors induced by Shh and Shh + N-myc with antibodies against vascular markers, von Willebrand Factor and PECAM-1 (CD31), we found immunoreactive staining only in mature blood vessels and not in tumor cells (Fig. 1H).

Stabilized N-myc strongly enhances Shh-induced tumor formation. Highly conserved, NH2-terminal phospho-acceptor sites have been implicated in Myc protein turnover. Phosphorylation of c-Myc at T58 or N-myc at T50 by GSK3ß precedes ubiquitination and degradation (18, 34, 35). Mutations surrounding the GSK3ß phosphorylation site in c-Myc occur in human malignant lymphomas and cause highly aggressive tumors in a mouse model of Burkitt's lymphoma, indicating conservation of this regulatory mechanism in mouse models of human disease (36). Mutation of T50 or S54, the priming site for GSK3ß, enhances N-myc stability and promotes proliferation of cultured GNPs (18). Because IGF activates Akt to inhibit GSK3ß, we speculated that the enhancing effect of IGF-II and Akt on Shh-induced medulloblastoma formation (15) might result from the ability of PI3K pathway activation to stabilize N-myc by inhibiting GSK3ß.

We asked how N-myc with a nonphosphorylatable alanine substitution at T50 affected Shh-mediated medulloblastoma formation. Tumor incidence increased to 78% (P = 0.0018) when we used the RCAS-N-mycT50A vector to express this stabilized allele of N-myc in nestin-expressing neural progenitor cells together with RCAS-Shh (Table 1). The induced tumors were highly aggressive. The median survival for mice that developed tumors was shorter following transfer of Shh + N-mycT50A (22 days) compared with Shh + N-myc (47 days; P = 0.0006 by t test). A trend toward increased proliferation was shown by immunostaining for Ki67, a nuclear protein expressed by actively dividing cells. The percentage of Ki67+ cells (mitotic index) was 37% (± 7%) in Shh + N-mycT50A–induced tumors compared with 17% (± 3%) in Shh + N-myc–induced tumors (P = 0.07 by t test; Table 1).

Immunoperoxidase staining with N-myc-specific antibody C19 of tumor-bearing brain sections from mice injected with RCAS-Shh + RCAS-N-mycT50A showed nuclear or cytoplasmic immunoreactivity in 100% of tumor cells (Fig. 2A). To detect ectopic (RCAS-mediated) gene expression, we induced medulloblastomas in Ntv-a mice with epitope-tagged versions of N-mycT50A and Shh (c-Myc-tagged N-mycT50A and HA-tagged Shh). When we probed brain tissue sections with antibodies directed against the tags, we found expression of RCAS-N-mycT50A (nuclear or cytoplasmic) in ~50% of tumor cells (Fig. 2B and C) and RCAS-Shh (cytoplasmic) in <30% (Fig. 2D). Thus, the induced tumors are mixtures of clones originating from cells infected with Shh alone or in combination with N-myc. Consistent with our previous report on medulloblastomas induced by Shh + c-Myc, these results suggest that Shh, a secreted protein, may exert a paracrine effect on neighboring cells (12). Figure 2C and D shows ectopic (RCAS-mediated) expression of Shh and N-myc in tumor cells abutting the cortical surface of the cerebellum. We did not see transgene expression in deeper layers of the cerebellum, except for tumors cells infiltrating the molecular layer. These findings support an origin of the induced tumors from GNPs in the EGL.


Figure 2
View larger version (82K):
[in this window]
[in a new window]
  		Figure 2. Expression of N-myc, Shh, and cyclin D2 in mouse medulloblastomas. A, immunoperoxidase staining of medulloblastoma induced by untagged RCAS vectors for Shh and N-myc showing expression of endogenous and retroviral N-myc in tumor cell nuclei. B to D, immunoperoxidase staining of medulloblastoma induced by RCAS-mediated transfer of HA-tagged Shh and c-Myc-tagged N-mycT50A. B, 9E10 antibody detects cytoplasmic (arrow) and nuclear (arrowhead) staining of tumor cells, indicating expression of retroviral N-myc. C and D, ectopic (RCAS-mediated) expression of N-mycT50A (C) and Shh (D) in tumor cells but not in adjacent cerebellum. E, immunoblotting analysis of cerebellum (C) and forebrain (F) from three mice injected with Flag-tagged RCAS-N-mycT50A and untagged RCAS-Shh. Tumors were visible in the cerebella of mice D3.1 and A3, but not in D3.2. Probing with anti-Flag antibody showed immunoreactivity in the tumor tissue, thus verifying RCAS-mediated transfer and expression of N-myc. Protein samples showed correspondingly high levels of total N-myc (endogenous + retroviral) and endogenous cyclin D2 in the tumor-bearing cerebella. ß-Tubulin immunoreactivity shows equivalent loading of gel lanes. F, immunoperoxidase staining of medulloblastoma induced by Shh + N-mycT50A, showing nuclear expression of cyclin D2. Bar: 19 µm (A), 12 µm (B), 97 µm (C and D), and 38 µm (F).

 
To obtain additional evidence for transfer and expression of retroviral N-myc, we removed the brains from three mice, injected 3 months earlier with Flag-tagged RCAS-N-mycT50A in combination with untagged RCAS-Shh. The brain from one mouse (D3.1) showed a large tumor that replaced half of the cerebellum. A second mouse (A3) showed a smaller, but still grossly visible, tumor. No tumor was visible in the third mouse (D3.2).

We prepared protein lysates from the cerebellum and forebrain of each mouse and probed an immunoblot with an antibody directed against the Flag epitope. Flag immunoreactivity was detected in the tumor-bearing cerebella but not in cerebellum or forebrain tissue from mouse D3.2, which lacked a visible tumor (Fig. 2E). Taken together, these results indicate that stabilization of N-myc, by preventing GSK3ß-mediated phosphorylation and degradation, powerfully enhanced medulloblastoma formation.

N-myc positively regulates G1 cyclins to enhance proliferation in medulloblastoma. Overexpressing N-myc in cultured GNPs promotes cell cycle progression in the absence of Shh signaling (19). This can be attributed at least partly to N-myc induction of D-type cyclins, which promote progression through the G1 phase of the cell cycle (37). Impaired cerebellar neurogenesis occurs in mice lacking cyclin D2, and this cyclin is strikingly down-regulated in mice lacking N-myc in the central nervous system (21, 38). We found high levels of cyclin D2 in the grossly visible mouse tumors induced by Shh + N-mycT50A (Fig. 2E). Immunocytochemistry showed intense cyclin D2 staining in the majority of tumor cell nuclei (Fig. 2F). These data suggest that up-regulation of N-myc in medulloblastoma promotes continuous cell cycle progression, at least partly through prolonged G1 cyclin up-regulation. N-myc is likely to have additional downstream effectors promoting GNP proliferation because overexpression of D-type cyclins alone is not sufficient for GNP proliferation in vitro (20).

Shh is required for GNP transformation. In proliferating GNPs, Shh signaling induces N-myc gene transcription (19, 20) and IGF/PI3K signaling stabilizes the N-myc protein (18). Because Shh and IGF cooperate to promote medulloblastoma formation in mice (15), we wished to determine whether their combined effects on N-myc expression and stability were the principle determinants of tumorigenesis in vivo or if additional elements were required. We injected the cerebella of newborn Ntv-a mice with cell pellets producing RCAS-N-mycT50A viruses alone. We did not detect tumors in these animals. Thus, whereas both N-myc and N-mycT50A strongly synergized with Shh in promoting medulloblastoma formation, increased levels of N-myc alone were not sufficient to induce tumor formation.

These results suggest that Shh may have transforming effects on GNPs, distinct from increasing levels of N-myc mRNA. Alternatively, Shh and IGF may both provide transforming cues and N-myc may cooperate with either pathway to render GNPs susceptible to transformation. To address this possibility, we asked whether N-myc could cooperate with IGF to induce medulloblastoma. We could not induce tumors by injecting mice with RCAS-N-myc in combination with RCAS-IGF-II or its downstream effector, RCAS-Akt (Table 1). These data indicate that Shh has transforming functions that are not supplied by IGF/PI3K signaling in GNPs.

Members of the Gli family of transcription factors are well-known transcriptional targets of Shh and they are required for mediating the effects of Shh during embryonic development (reviewed in ref. 39). Gli1, a positive regulator of Shh signaling, has been implicated in spontaneous medulloblastoma formation in Patched-deficient mice (10, 25). However, Gli1 is not necessary for induction of medulloblastoma in a different mouse model involving ectopic expression of Shh in utero (11). Both of these models rely on fetal alteration of gene expression whereas medulloblastomas in humans arise during postnatal cerebellar development. We wished to address the role of Gli1 in GNP transformation during the appropriate developmental window using RCAS-mediated gene transfer. Full-length Gli1 cDNA is it too large for efficient RCAS packaging (3.3 kB). Therefore, we designed an RCAS vector to transfer and express a deleted version of Gli1, termed GLI(-AT), which retains full transcriptional activity (ref. 24; Fig. 3A). RCAS-GLI(-AT) retroviruses were also highly infectious and expressed in DF-1 cells (Fig. 3B).


Figure 3
View larger version (37K):
[in this window]
[in a new window]
  		Figure 3. Functional analysis of RCAS-Gli1. A, GLI(-AT) activates transcription of a luciferase reporter in HeLa cells. HeLa cells were cotransfected with reporter plasmid (8XGLI-1c-luc) and varying amounts of RCAS (negative control), RCAS-GLI(-AT), RCAS-GLI(-AT) + Myc, CMV-GLI1 (positive control), or CMV-GLI1(-TAD) (negative control). Columns, mean of triplicate experiments; bars, SD. *, P < 0.05, statistically significant difference in luciferase activity compared with empty RCAS vector. B, DF-1 cells were exposed to infectious supernatant containing RCAS-GLI(-AT) + Myc and probed with 9E10 antibody specific for the c-Myc epitope tag on the encoded Gli1 protein. Immunoreactive staining was visible in infected cells (+) but not in uninfected controls (–). Immunoblotting with 9E10 showed a 120-kDa band corresponding to Myc-tagged Gli1.

 
In contrast to Shh alone, which promotes medulloblastoma formation in ~15% of injected mice, RCAS-GLI(-AT) did not induce medulloblastoma in any animals (Table 1). This suggests that Shh promotes oncogenesis through mechanisms separate from or in addition to induction of Gli1. One of these mechanisms may involve up-regulation of N-myc. Whether Shh induces N-myc through Gli1 signaling is not yet resolved. Thus, we next asked if Gli1 could cooperate with N-myc to promote medulloblastoma formation. However, we found that this was not the case (Table 1). We concluded from these results that Gli1 is not a critical mediator of Shh tumorigenic effects in GNPs.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
We show here that N-myc, a transcriptional target of Shh in GNPs, can replace IGF/PI3K signaling in cooperating with Shh to promote medulloblastoma formation in mice in vivo. Ectopic expression of an N-myc mutant, resistant to the proteolytic effects of GSK3ß, significantly enhanced Shh-induced medulloblastoma formation. This suggests that an important role of the IGF/PI3K pathway is to increase levels of N-myc, at least partly through its stabilizing effects resulting from GSK3ß inhibition.

Mice in which the N-myc gene has been constitutively knocked out fail to survive beyond midgestation because multiple defects arise during organogenesis (40, 41). These developmental defects are particularly severe in the nervous system. A vital role for N-myc in governing cerebellar development was shown by Knoepfler et al. (21) who created conditional knockout mice in which N-myc was deleted in nestin-expressing, neural progenitors. These mice survived to adulthood, but with marked reduction in brain size, which was strongly evident in the cerebellum. Cerebellar hypoplasia correlated with progenitor cell depletion and increased levels of cyclin-dependent kinase inhibitors. In cultured GNPs, blocking N-myc function results in reduced proliferation (19, 20). Conversely, ectopic expression of N-myc enhances Shh-induced proliferation in vitro, indicating that GNPs are highly sensitive to levels of N-myc in regulating proliferation (18). Our finding that enhancing levels of N-myc increases Shh-induced medulloblastoma formation suggests that heightened or protracted expression of N-myc makes GNPs highly susceptible to additional transforming events.

Hyperactive IGF signaling plays a supporting role in medulloblastoma formation but it is not sufficient for tumor induction (15). Transgenic mice in which IGF-I expression is driven to high levels by the neurologically active Igf2 gene promoter do not develop tumors. Instead, they develop enlarged cerebella containing dramatically increased numbers of granule neurons (14). This hyperplastic response stems from the ability of IGF to promote both survival and proliferation of GNPs (42, 43). It is possible that the complementary transforming function supplied by Shh is its ability to suppress differentiation, an important role of Shh signaling in GNPs (44). Our observation that N-myc is a potent substitute for IGF/PI3K signaling in cooperating with Shh to induce medulloblastoma is consistent with the in vitro finding that PI3K signaling in GNPs inhibits GSK3ß-dependent phosphorylation and turnover of N-myc protein and thus increases accumulation of this oncogenic, cell cycle–stimulating transcription factor (18). Alternatively, IGF and N-myc might independently cooperate with Shh to enhance tumor formation through undetermined mechanisms.

In cultured GNPs, retrovirally expressed N-myc can replace Shh in promoting cell cycle progression, suggesting that N-myc transcriptional targets are likely to be downstream mediators of Shh proliferative effects (19, 20). However, ectopic expression of N-myc or upstream PI3K pathway activators, IGF-II and Akt, was not sufficient to induce medulloblastoma formation without coexpression of Shh. This suggests that Shh has additional targets that complement the pro-proliferative effects of N-myc to induce neoplastic transformation in vivo. Transcriptional profiling studies have shown that stimulation of GNPs by Shh up-regulates the expression of broad classes of genes governing such diverse functions as cell cycle progression, differentiation, DNA replication, and ribosome assembly (20, 45). It is not known which of these Shh target genes might provide the complementary oncogenic functions to N-myc.

The transcription factor Gli1, a direct target of Shh, has been implicated in medulloblastoma (10). However, the role of Gli1 in GNP proliferation is questionable because mice lacking Gli1 show no cerebellar abnormalities (46). It has recently been suggested that Gli1 plays a role in tumor formation in Patched+/– mice (47). However, these authors also found evidence of increased Gli2 activity in medulloblastomas from Patched+/– mice, and others have shown that Gli2 mediates effects of aberrant Shh pathway activation during development (49). Gli1 is dispensable for Shh-mediated medulloblastoma formation in Patched-wild-type mice (11), which is consistent with our inability to induce medulloblastoma by RCAS-mediated expression of Gli1. Thus, resolving the individual roles of Gli1 and Gli2 in mediating the transforming functions of Shh in GNPs will require further investigation.

As shown in Fig. 4, it is possible that Shh signaling is involved in tumor initiation but subsequent expansion of tumor cells is driven by Shh-mediated up-regulation of the IGF/PI3K pathway. The ability of Shh to activate this pathway is supported by the observations that IGF-II is required for medulloblastoma formation in Patched-deficient mice (49) and that PI3K signaling is activated in medulloblastomas induced by ectopic expression of Shh (15). Once activated, IGF/PI3K signaling would then promote N-myc stabilization and consequent cell cycle progression, in addition to playing other oncogenic roles, such as enhancing cell survival. This mechanism can be initiated by excess Shh signaling alone and magnified by the addition of ectopic N-myc.


Figure 4
View larger version (15K):
[in this window]
[in a new window]
  		Figure 4. Proposed model for synergy between Shh and IGF/PI3K signaling in medulloblastoma. IGF/PI3K signaling inhibits GSK3ß-mediated phosphorylation and consequent degradation of N-myc. Shh directly stimulates N-myc gene transcription. Shh may also activate the IGF/PI3K pathway via unknown intermediary molecules. In GNPs, the combined effect of these events is to increase N-myc protein levels, thereby stimulating G1 cell cycle progression and promoting tumorigenesis. Medulloblastomas can be induced by RCAS-mediated ectopic expression of Shh, but not of IGF-II, Akt, or N-myc, indicating that Shh has unique and essential transforming function.

 
Although Fig. 4 depicts a linear pathway connecting IGF and Akt with N-myc, the oncogenic effects of IGFs in human brain tumors are probably more complex. IGFs can activate multiple downstream effectors, including the mitogen-activated protein kinase (MAPK) pathway. In cerebellar neurons, however, IGF-dependent survival is mediated by PI3K signaling, not MAPK signaling (42). Furthermore, a central role of PI3K signaling in mediating the oncogenic effects of IGF is supported by our previous report that activated Akt can functionally replace IGF in enhancing Shh-induced medulloblastoma formation (15). It will be difficult to unravel the distinct roles played by N-myc and IGF in Shh-induced tumorigenesis in vivo due to the neural defects in constitutive N-myc knockout mice (40, 41) and the marked cerebellar hypoplasia in conditional knockouts (21).

Modeling signal transduction pathways using the RCAS/tv-a system not only provides insight into the molecular pathogenesis of human medulloblastoma but also identifies potential therapeutic targets. Independent studies have shown that N-myc mRNA and protein levels are elevated in human medulloblastomas (13, 22). A broader role for Myc proteins is suggested by our previous report that c-Myc also cooperates with Shh to enhance medulloblastoma formation (12). The histology of tumors induced by Shh + c-Myc is identical to that described in this report, suggesting that N-myc and c-Myc may perform similar functions in cooperating with Shh. Because the intracellular concentration of c-Myc is regulated by GSK3ß-catalyzed phosphorylation reactions analogous to those that regulate N-myc turnover, a general therapeutic strategy for medulloblastoma could involve suppression of Myc levels in tumor cells by inhibiting PI3K signaling.


   Acknowledgments
 
Grant support: NIH Cancer Training Grant T32 CA093247 (S.R. Browd), The Sontag Foundation (A.M. Kenney), The Brain Tumor Society (D.W. Fults), The Charlotte Geyer Foundation (D.W. Fults), and NIH grant CA108622 (D.W. Fults).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   Footnotes
 
Note: S.R. Browd and A.M. Kenney contributed equally to this work.

Received 6/29/05. Revised 11/26/05. Accepted 12/14/05.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Marino S. Medulloblastoma: developmental mechanisms out of control. Trends Mol Med 2005;11:17–22.[CrossRef][Medline]
  2. Oliver TG, Read TA, Kessler JD, et al. Loss of patched and disruption of granule cell development in a pre-neoplastic stage of medulloblastoma. Development 2005;132:2425–39.[Abstract/Free Full Text]
  3. Lee A, Kessler JD, Read TA, et al. Isolation of neural stem cells from the postnatal cerebellum. Nat Neurosci 2005;8:723–9.[CrossRef][Medline]
  4. Hatten ME, Heintz N. Mechanisms of neural patterning and specification in the developing cerebellum. Annu Rev Neurosci 1995;18:385–408.[Medline]
  5. Ho KS, Scott MP. Sonic hedgehog in the nervous system: functions, modifications and mechanisms. Curr Opin Neurobiol 2002;12:57–63.[CrossRef][Medline]
  6. de Pablo F, de la Rosa EJ. The developing CNS: a scenario for the action of proinsulin, insulin and insulin-like growth factors. Trends Neurosci 1995;18:143–50.[CrossRef][Medline]
  7. Raffel C, Jenkins RB, Frederick L, et al. Sporadic medulloblastomas contain PTCH mutations. Cancer Res 1997;57:842–5.[Abstract/Free Full Text]
  8. Pietsch T, Waha A, Koch A, et al. Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res 1997;57:2085–8.[Abstract/Free Full Text]
  9. Del Valle L, Enam S, Lassak A, et al. Insulin-like growth factor I receptor activity in human medulloblastomas. Clin Cancer Res 2002;8:1822–30.[Abstract/Free Full Text]
  10. Goodrich LV, Milenkovic L, Huggins KM, Scott MP. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997;277:1109–13.[Abstract/Free Full Text]
  11. Weiner HL, Bakst R, Hurlbert MS, et al. Induction of medulloblastomas in mice by Sonic hedgehog, independent of Gli1. Cancer Res 2002;62:6385–9.[Abstract/Free Full Text]
  12. Rao G, Pedone CA, Coffin CM, Holland EC, Fults DW. c-Myc enhances Sonic hedgehog-induced medulloblastoma formation from nestin-expressing neural progenitors in mice. Neoplasia 2003;5:198–204.[Medline]
  13. Hallahan AR, Pritchard JI, Hansen S, et al. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res 2004;64:7794–800.[Abstract/Free Full Text]
  14. Ye P, Xing Y, Dai Z, D'Ercole AJ. In vivo actions of insulin-like growth factor-I (IGF-I) on cerebellum development in transgenic mice: evidence that IGF-I increases proliferation of granule cell progenitors. Brain Res Dev Brain Res 1996;95:44–54.[Medline]
  15. Rao G, Pedone CA, Del Valle L, Reiss K, Holland EC, Fults DW. Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene 2004;23:6156–62.[CrossRef][Medline]
  16. Federspiel MJ, Bates P, Young JAT, Varmus HE, Hughes SH. A system for tissue-specific gene targeting: transgenic mice susceptible to subgroup A avian leukosis virus-based retroviral vectors. Proc Natl Acad Sci U S A 1994;91:11241–5.[Abstract/Free Full Text]
  17. Lendahl U, Zimmerman LB, McKay RDG. CNS stem cells express a new class of intermediate filament protein. Cell 1990;60:585–95.[CrossRef][Medline]
  18. Kenney AM, Widlund HR, Rowitch DH. Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors. Development 2004;131:217–28.[Abstract/Free Full Text]
  19. Kenney AM, Cole MD, Rowitch DH. Nmyc up-regulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors. Development 2003;130:15–28.[Abstract/Free Full Text]
  20. Oliver TG, Grasfeder LL, Carroll AL, et al. Transcriptional profiling of the sonic hedgehog response: a critical role for N-myc in proliferation of neuronal precursors. Proc Natl Acad Sci U S A 2003;100:7331–6.[Abstract/Free Full Text]
  21. Knoepfler PS, Cheng PF, Eisenman RN. N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes Dev 2002;16:2699–712.[Abstract/Free Full Text]
  22. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002;415:436–42.[CrossRef][Medline]
  23. Holland EC, Hively WP, DePinho RA, Varmus HE. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 1998;12:3675–85.[Abstract/Free Full Text]
  24. Yoon JW, Liu CZ, Yang JT, Swart R, Iannaccone P, Walterhouse D. GLI activates transcription through a herpes simplex viral protein 16-like activation domain. J Biol Chem 1998;273:3496–501.[Abstract/Free Full Text]
  25. Wetmore C, Eberhart DE, Curran T. The normal patched allele is expressed in medulloblastomas from mice with heterozygous germ-line mutation of patched. Cancer Res 2000;60:2239–46.[Abstract/Free Full Text]
  26. Easter SS, Jr., Ross LS, Frankfurter A. Initial tract formation in the mouse brain. J Neurosci 1993;13:285–99.[Abstract]
  27. Mullen RJ, Buck CR, Smith AM. NeuN, a neuronal specific nuclear protein in vertebrates. Development 1992;116:201–11.[Abstract]
  28. Segal RA, Goumnerova LC, Kwon YK, Stiles CD, Pomeroy SL. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci U S A 1994;91:12867–71.[Abstract/Free Full Text]
  29. Coffin CM, Wick MR, Braun JT, Dehner LP. A clinicopathological and immunohistochemical analysis of 53 cases of medulloblastoma with emphasis on synaptophysin expression. Mod Pathol 1990;3:164–70.[Medline]
  30. Lu QR, Yuk D, Alberta JA, et al. Sonic hedgehog-regulated oligodendrocyte lineage genes encoding bHLH proteins in the mammalian central nervous system. Neuron 2000;25:317–29.[CrossRef][Medline]
  31. Dahmane N, Ruiz-i-Altaba A. Sonic hedgehog regulates the growth and patterning of the cerebellum. Development 1999;126:3089–100.[Abstract]
  32. Okano-Uchida T, Himi T, Komiya Y, Ishizaki Y. Cerebellar granule cell precursors can differentiate into astroglial cells. Proc Natl Acad Sci U S A 2004;101:1211–6.[Abstract/Free Full Text]
  33. Mokry J, Cizkova D, Filip S, et al. Nestin expression by newly formed human blood vessels. Stem Cells Dev 2004;13:658–64.[CrossRef][Medline]
  34. Gregory MA, Qi Y, Hann SR. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem 2003;278:51606–12.[Abstract/Free Full Text]
  35. Welcker M, Orian A, Jin J, et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci U S A 2004;101:9085–90.[Abstract/Free Full Text]
  36. Hemann MT, Bric A, Teruya-Feldstein J, et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 2005;436:807–11.[CrossRef][Medline]
  37. Ciemerych MA, Kenney AM, Sicinska E, et al. Development of mice expressing a single D-type cyclin. Genes Dev 2002;16:3277–89.[Abstract/Free Full Text]
  38. Huard JM, Forster CC, Carter ML, Sicinski P, Ross ME. Cerebellar histogenesis is disturbed in mice lacking cyclin D2. Development 1999;126:1927–35.[Abstract]
  39. Ruiz i Altaba A, Nguyen V, Palma V. The emergent design of the neural tube: prepattern, SHH morphogen and GLI code. Curr Opin Genet Dev 2003;13:513–21.[CrossRef][Medline]
  40. Charron J, Malynn BA, Fisher P, et al. Embryonic lethality in mice homozygous for a targeted disruption of the N-myc gene. Genes Dev 1992;6:2248–57.[Abstract/Free Full Text]
  41. Stanton BR, Perkins AS, Tessarollo L, Sassoon DA, Parada LF. Loss of N-myc function results in embryonic lethality and failure of the epithelial component of the embryo to develop. Genes Dev 1992;6:2235–47.[Abstract/Free Full Text]
  42. Dudek H, Datta SR, Franke TF, et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 1997;275:661–5.[Abstract/Free Full Text]
  43. Lin X, Bulleit RF. Insulin-like growth factor I (IGF-I) is a critical trophic factor for developing cerebellar granule cells. Brain Res Dev Brain Res 1997;99:234–42.[CrossRef][Medline]
  44. Wechsler-Reya RJ, Scott MP. Control of neuronal precursor proliferation in the cerebellum by sonic hedgehog. Neuron 1999;22:103–14.[CrossRef][Medline]
  45. Zhao Q, Kho A, Kenney AM, Yuk Di DI, Kohane I, Rowitch DH. Identification of genes expressed with temporal-spatial restriction to developing cerebellar neuron precursors by a functional genomic approach. Proc Natl Acad Sci U S A 2002;99:5704–9.[Abstract/Free Full Text]
  46. Park HL, Bai C, Platt KA, et al. Mouse Gli1 mutants are viable but have defects in SHH signaling in combination with a Gli2 mutation. Development 2000;127:1593–605.[Abstract]
  47. Kimura H, Stephen D, Joyner A, Curran T. Gli1 is important for medulloblastoma formation in Ptc1+/– mice. Oncogene 2005;24:4026–36.[Medline]
  48. Bai CB, Auerbach W, Lee JS, Stephen D, Joyner AL. Gli2, but not Gli1, is required for initial Shh signaling and ectopic activation of the Shh pathway. Development 2002;129:4753–61.[Medline]
  49. Hahn H, Wojnowski L, Specht K, et al. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomysosarcoma. J Biol Chem 2000;275:28341–4.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Genes Dev.Home page
J. D. Kessler, H. Hasegawa, S. N. Brun, B. A. Emmenegger, Z.-J. Yang, J. W. Dutton, F. Wang, and R. J. Wechsler-Reya
N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma
Genes & Dev., January 15, 2009; 23(2): 157 - 170.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. B. Corcoran, T. Bachar Raveh, M. T. Barakat, E. Y. Lee, and M. P. Scott
Insulin-like Growth Factor 2 Is Required for Progression to Advanced Medulloblastoma in patched1 Heterozygous Mice
Cancer Res., November 1, 2008; 68(21): 8788 - 8795.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. J. Binning, T. Niazi, C. A. Pedone, B. Lal, C. G. Eberhart, K. J. Kim, J. Laterra, and D. W. Fults
Hepatocyte Growth Factor and Sonic Hedgehog Expression in Cerebellar Neural Progenitor Cells Costimulate Medulloblastoma Initiation and Growth
Cancer Res., October 1, 2008; 68(19): 7838 - 7845.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
X. Fan and C. G. Eberhart
Medulloblastoma Stem Cells
J. Clin. Oncol., June 10, 2008; 26(17): 2821 - 2827.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
D. Hambardzumyan, O. J. Becher, M. K. Rosenblum, P. P. Pandolfi, K. Manova-Todorova, and E. C. Holland
PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo
Genes & Dev., February 15, 2008; 22(4): 436 - 448.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Boller, A. Schramm, K. T. Doepfner, T. Shalaby, A. O. von Bueren, A. Eggert, M. A. Grotzer, and A. Arcaro
Targeting the Phosphoinositide 3-Kinase Isoform p110{delta} Impairs Growth and Survival in Neuroblastoma Cells
Clin. Cancer Res., February 15, 2008; 14(4): 1172 - 1181.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
J. M. de Bont, R. J. Packer, E. M. Michiels, M. L. d. Boer, and R. Pieters
Biological background of pediatric medulloblastoma and ependymoma: A review from a translational research perspective
Neuro-oncol, January 1, 2008; 10(6): 1040 - 1060.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. D. McCall, C. A. Pedone, and D. W. Fults
Apoptosis Suppression by Somatic Cell Transfer of Bcl-2 Promotes Sonic Hedgehog-Dependent Medulloblastoma Formation in Mice
Cancer Res., June 1, 2007; 67(11): 5179 - 5185.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. P. Morton, M. E. Mongeau, D. S. Klimstra, J. P. Morris, Y. C. Lee, Y. Kawaguchi, C. V. E. Wright, M. Hebrok, and B. C. Lewis
Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis
PNAS, March 20, 2007; 104(12): 5103 - 5108.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Browd, S. R.
Right arrow Articles by Fults, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Browd, S. R.
Right arrow Articles by Fults, D. W.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online